Search Publications

Publications

TITLE
Alert

SEC Urges Companies to Provide Robust, Forward-Looking Disclosure on COVID-19 Impact in Earnings Releases and Investor Calls

In anticipation of the raft of earnings releases and analyst and investor calls that will take place in the next few weeks, the U.S. Securities and Exchange Commission (SEC) issued a public statement in which SEC Chairman Jay Clayton and Director of the Division of Corporation Finance William Hinman urge issuers to provide robust, forward-looking disclosures regarding the impact of COVID-19 in their upcoming earnings releases and analyst and investor calls.

Blog Post
Alert

COVID-19: States Attempt to Shift Economic Burden to Insurance Industry with New Legislation on Business Interruption Coverage

In recent weeks, an increasing number of state legislatures have taken drastic measures to force the insurance industry to shoulder much of the burden of the economic downturn brought on by the global COVID-19 pandemic.

Blog Post

COVID-19 or Not, CPSC Keeps Chugging Along

Schiff Hardin Product Liability and Mass Torts Blog

Blog Post
Alert

Novel Virus Brings Novel Coverage Theories

Like new cases of COVID-19, the number of business interruption suits appears to be increasing exponentially. In the last few weeks, dozens of plaintiffs in at least six lawsuits across four states have sought insurance coverage for business losses associated with the COVID-19 outbreak.

Alert

SEC Provides Informal Guidance on COVID-19 Relief Regarding Incorporation by Reference of Information from Proxy Materials into Form 10-K

On March 25, the U.S. Securities and Exchange Commission (SEC) granted public company regulatory relief and issued Staff guidance regarding disclosure obligations in light of the continued complications associated with the COVID-19 pandemic.

Blog Post

Five Effective Ways Companies Can Communicate with Customers During COVID-19

Schiff Hardin Product Liability and Mass Torts Blog

Blog Post

EPA to Relax Civil Enforcement for Non-Compliance Due to COVID-19 Pandemic

Schiff Hardin Energy & Environmental Law Adviser

Blog Post

CARES Act: Expansion of Unemployment Insurance and Benefits

Schiff Hardin Employment Law Landscape

Alert

If Successful, Teva Suit Could Decrease Generic Competition

Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

Blog Post

CARES Act: Four Key Labor Provisions Employers Need to Know

Schiff Hardin Employment Law Landscape